Inhibition of neutrophil activation by  p ‐bromophenacyl bromide and its effects on phospholipase A 2 by Duque, Ricardo E. et al.
Br. J. Pharmac. (1986), 88, 463-472
Inhibition of neutrophil activation byp-bromophenacyl
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1 In an effort to elucidate the nature ofthe inhibitory effects ofp-bromophenacyl bromide (pBPB) on
neutrophil stimulation, we have examined its effects on several stages of stimulus-response coupling.
2 Pretreatment of rat neutrophils with pBPB resulted in a dose- and time-dependent irreversible
inhibition of both N-formylmethionyl-leucylphenylalanine (fMet-Leu-Phe)-induced lysosomal
enzyme release and change in transmembrane potential.
3 Inhibition of the biological responses to the chemotactic peptide fMet-Leu-Phe was not due to
receptor inactivation since fMet-Leu-[3H]-Phe binding to the formyl peptide receptor was not
significantly altered by pBPB pretreatment.
4 Inhibition by pBPB of phorbol myristate acetate (PMA)-induced changes in transmembrane
potential and the generation of superoxide (02) was also observed.
5 pBPB treatment appeared to inhibit activation of the NADPH oxidase without a direct effect on
the oxidase itself.
6 This inhibitory effect was not accompanied by cell death or decrease in cellular titratable sulphydryl
groups (at least at doses <20 pM).
7 There was, however, significant inhibition of a membranous fraction of fMet-Leu-Phe-induced
phospholipase A2 activity by pretreatment with 10 pM pBPB, although total cellular phospholipase A2
was only minimally (<20% inhibition) affected.
8 These data would indicate that pBPB inhibits an early event associated with stimulus-response
coupling in rat polymorphonuclear. leukocytes (i.e. change in transmembrane potential). The
inhibitory effects ofpBPB may be secondary to the inhibition ofa critical membranous fraction ofcell
bound phospholipase A2 activity or its activation, necessary for the initiation of cell activation.
Introduction
Stimulation of polymorphonuclear leukocytes by
chemotactic or phagocytic stimuli results in a series of
reactions that eventually terminate in chemotaxis and/
or phagocytosis with associated generation of oxygen
radicals and release ofgranule bound enzymes such as
lysozyme and P-glucuronidase (Weissman et al., 1980).
Additionally, oxidation products of arachidonic acid
via the cyclo-oxygenase, and lipoxygenase pathways
are formed which can in turn modulate the cellular
responses (Goetzl, 1980).
The mechanisms involved in the process of
stimulus-secretion coupling have been partially
elucidated (Weissman et al., 1980). Among these,
depolarization of the transmembrane potential as
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assessed by an increase in the fluorescence intensity of
the optical probe of membrane potential 3-3'-
dipropylthiadicarbocyanine iodide, [diS-C3-(5)], is de-
tectable within seconds of exposure of neutrophils to
different stimuli (Sklar et al., 1980). This event can be
correlated to the functional response phase of neutro-
phil stimulation (Duque et al, 1983). Moreover, using
protease inhibitors, such as L-l-tosylamide-2-phen-
ylethyl chloromethyl ketone (TPCK), we have recently
shown that a chymotrypsin-like activity is required for
cell stimulation including transmembrane potential
changes. This inhibition can be overcome by exposure
of TPCK-treated neutrophils to the calcium iono-
phore A23187 in the presenceof > 1.5 mMCa
suggesting that the TPCK inhibitable activity precedes
a 2+ requiring step (Duque et al., 1983). This
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esterase activity may be related to the Ca2" dependent
(Derksen & Cohen, 1975) activation of a cell bound
phospholipase A2 (phosphatide 2-acyl-hydrolase,
EC 3.1.1.4), which has been identified in plasma
membranes of neutrophils (Victor et al., 1981). The
subsequent release of unesterified arachidonic acid
from cellular phospholipids by the activated phos-
pholipase A2 is considered to be an initial requirement
for the synthesis and secretion of prostaglandins and
other arachidonic acid metabolites (Kuehl & Egar,
1980). Arachidonic acid can also be released by the
combined action of phospholipase C and diacyl-
glycerol lipase (Bell et al., 1979).
Treatment of neutrophils with p-bromophenacyl
bromide (pBPB), an 'active site directed' inhibitor of
phospholipase A2 by alkylation of a histidine residue,
has been reported to inhibit superoxide generation and
enzyme release (Smolen& Weissman, 1980). Although
there is currently no evidence to indicate that the
neutrophil enzyme contains a histidine residue at its
active site, a likely target for this inhibition is the
membrane bound phospholipase A2 (Bormann et al.,
1984). Accordingly, we have investigated the effects of
p-bromophenacyl bromide on several physiological
responses associated with stimulus-response coupling
in rat neutrophils, and attempted to demonstrate the




Healthy, adult, male, Long-Evans rats (Charles River
Laboratory) (250 to 350 g) were used. Neutrophils
were elicited from the peritoneal cavity by use of a
solution of 1% oyster glycogen (Becker, 1972). Cell
suspensions were >95% neutrophils as assessed by
toluidine blue staining. All assays described below
were performed at least in duplicate, although most
were done in triplicate. Data in the various tables and
figures are typical of3-6 experiments performed on as
many different cell preparations.
Superoxide production and enzyme release
Superoxide was measured as the superoxide dismutase
inhibitable reduction of cytochrome c as described by
McCord & Fridovich (1969). Results are expressed as
nmol 0-106 cells-' 60 min-'. Calculation of the actual
amount of nmol of cytochrome c reduced was made
utilizing an extinction coefficient of 21.1 cm-'mM-'
for cytochrome c (reduced minus oxidized) at 550 nm.
Lysozyme, P-glucuronidase and lactic dehydrogenase
activities were measured as described previously
(Becker et al., 1977). Results were expressed as
percentage ofenzyme activity present in lysates ofcells
treated with 0.1% Triton X-100.
Preparation of subcellular particles and NADPH
oxidase assay
In selected experiments the NADPH oxidase activity
was determined in the 27,000 g particle fraction of
sonicated neutrophils as previously described (Mc-
Phail et al., 1976). Briefly, rat neutrophils were divided
into two aliquots. One was treated with 1OgM pBPB
from (10-2 M stock solutions made in absolute eth-
anol) for 10 min at room temperature, washed, and
followed by stimulation with phorbol myristate
acetate (PMA, 200mgml-') for 10min at 37°C. A
second group was treated with PMA alone. Following
sonication and low speed centrifugation to remove
intact cells and nuclei, the 27,000 g pellet was obtained
and designated as subcellular particles. Subcellular
particles from PMA-treated cells were also prepared
and treated with pBPB (1I0 1M) for 10 min at room
temperature before assay for NADPH oxidase. The
ability of 50 Ml of each preparation to produce
superoxide dismutase-inhibitable O2 after incubation
for 15 min at room temperature in the presence of
NADPH was determined. Particles from non-PMA-
stimulated cells routinely produced less than 2 nmol
0° mg-' protein.
Membrane potential changes
Membrane potential changes were measured as
previously described (Duque et al., 1983). Neutrophils
(2 x 106) were equilibrated for 3-4min with
2 x 10-6M diS-C3-(5), in a Varian SF-330 spectro-
fluorometer at 37°C, with constant stirring. The
excitation wavelength was 622 nm and the emission
wavelength, 665 nm, with bandwidths of 10 nm. Final
concentrations of dimethyl sulphoxide (Me2SO) and
ethanol did not exceed 0.1%. Stimuli were added after
equilibration and the fluorescence monitored for
6-7 min using a chart recorder. Data are expressed as
the maximal change in fluorescence (AF). Exposure of
cell suspensions to the dye never exceeded 10 min. The
resting membrane potential was calculated by the 'null
point' method (Laris et al., 1976), based on the
external potassium concentration [K+] at which there
is no change in fluorescence intensity upon the addi-
tion of valinomycin (2 x 10-6M) in the presence and
absence of pBPB (5 gM for 10 min at 37'C).
diS-C3-(5) has been reported to exert toxic effects on
Ehrlich ascites tumour cells by rapidly depleting them
of ATP in glucose-free medium (Smith et al., 1981).
Accordingly, we measured ATP in suspensions of
neutrophils as assessed by the chemiluminescent res-
ponse in the luciferrin-luciferase system (Stanley &
Williams, 1969). Under the conditions of our experi-
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ments (i.e. buffer with 5 mM glucose), we detected ATP
values that were within 10% of control values up to
30 min after exposing the cells to the dye. Cell death as
assessed by inability to exclude Trypan blue was
minimal (> 90% viability) under these conditions of
incubation.
Since this carbocyanine dye is also expected to
partition in mitochondrial membranes, the observed
net change in fluorescence may have some contribu-
tion from changes in potential across mitochondrial
membranes. However, this contribution, if any, is
minimal because PMA-induced changes in diS-C3-(5)
fluorescence is not significantly affected by anaerobic
conditions (Whitin et al., 1980) which would have
dramatic impact on mitochrondrial potential.
Sulphydryl group titration
Titration of free sulphydryl groups was accomplished
using 5,5'-dithiobis(2-nitrobenzoic acid) according to
Deakin et al. (1963). Cells with or without pBPB
pretreatment were reacted with this reagent (100 gM)
for 30 min at room temperature. The absorbence at
412 nm was determined and used to quantitate the
amount of free SH groups (Deakin et al., 1963).
Analysis offMet-Leu-[3H]-Phe binding
The following protocol was used to assess the effect of
pBPB on the time course of N-formylmethionyl-
leucyl-[3H]-phenylalanine (fMet-Leu-[3H]-Phe) bind-
ing. Neutrophils (2.0 x 107 cellsml') were prein-
cubated at 37TC for 15 min in buffer before the start of
each experiment. The cells were divided into two tubes,
one of which was treated with pBPB (10 gM final
concentration): 350 pI aliquots were then removed
from each tube at various times, placed into
12 x 75mm glass test tubes, diluted with 4 ml of ice
cold buffer (no dextrose) and centrifuged at 900 g for
8 min. The supernatants were discarded, and the cell
pellets were resuspended in 350 p1 of buffer, to which
10mM 2-deoxy-D-glucose and 109 mM NaN3 had been
added to minimize receptor internalization during the
binding studies (Marasco et al., 1983). Aliquots ofcells
(I00pl) were then incubated for 25 min at 24°C with
20 nM f Met-Leu-[3H]-Phe in siliconized glass
12 x 75 mm test tubes. After these preliminary studies,
binding studies were routinely performed by incubat-
ing 10 laM pBPB with cells for 15 min. The cells were
washed, resuspended to 2 x I07 cells ml' and
analyzed for fMet-Leu-[3H]-Phe binding under
equilibrium conditions as previously described
(Marasco et al., 1983). Only specific binding is des-
cribed in this paper. The cells were harvested by a glass
fiber vacuum filtration method and analyzed for cell
bound radioactivity. All data points represent the
means of triplicate determinations.
Phospholipase A2 assay
Phospholipase A2 assay was performed according to
Franson et al. (1974) with slight modification. L-aC-1-
Palmitoyl-2-[palmitoyl-9, 10-3H]-phosphatidylcholine
(30-60 Ci mmol- ) was used as substrate. Rat periton-
eal neutrophils (108) were treated with 10- 5M pBPB at
37°C for 15 min. Control cells were similarly incubated
in the absence of pBPB. Cells were then washed once
with 0.34M sucrose in 10mM Tris HCI pH 7.5, and
sonicated on ice at 30W in three bursts of 10 s each.
Cell breakage was better than 90% as monitored by
the microscope. After centrifugation at 600 g for
20 min, 4°C, the supernatant was further spun at
27,000 g for 20 min at 4°C. The supernatant and pellet
were collected and used for assay as the soluble and
particulate or membranous fractions (subcellular par-
ticles) respectively. Fractions of these samples
(equivalent to 2 x 106 cells) were incubated with
0.2 pCi substrate diluted with 5 nmol of cold phos-
phatidylcholine in a final volume of 0.5 ml. The buffer
contained 10mM CaC12 and 100 nM Tris HCI pH 8.0.
After 60 min at 37°C, the entire mixture was extracted
with CHCI3-CH30H containing 0.5 mg palmitic acid
as previously described (Blight & Dyer, 1959). The
extracts were dried under vacuum with a Speed Vac
(Savant Instruments) concentrator, resuspended in
200 pA of methanol and analysed by reverse phase
h.p.l.c. H.p.l.c. was performed using a Varian Ins-
truments Vista 5560 system with an SP-C18 (Varian
Instruments, Palo Alto, CA) 3 pm particle size
column (4.6mm x 15 cm). Elution at 0.8 mlmin-'
was undertaken using isocratic conditions of 90%
methanol and 10% water at 40°C. Detection of the
effluent was by an on-line radioactive detector
(Radiomatic, Tampa, FL). Under these conditions,
palmitic acid eluted at 13.5min after injection, as
ascertained by use of pure palmitic acid. For positive
control, 20 ptg of porcine pancreatic phospholipase A2
was used, and negative control contained only buffer.
The negative control exhibited negligible release of
radioactive palmitic acid. Data were expressed as
relative integration units (under the palmitic acid peak
at 13.5 min), which were the output from the Vista 402
data processing unit. A unit of activity was defined as
106 relative integration units of the palmitic acid peak.
Normalization was to per 107 cells.
Materials
Cytochrome c (type III) from horse heart, superoxide
dismutase, Micrococcus lysodeikticus, sodium
pyruvate (22mM), NADH, valinomycin, N-formyl-
methionyl-leucylphenylalanine (fMet Leu Phe), pBPB,
phenophthalein P-glucuronic acid, NADPH, 5,5'-
dithiobis (2-nitrobenzoic acid), palmitic acid and
porcine pancreatic phospholipase A2 were obtained from
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Sigma Chemical Co. (St. Louis, MO). diS-C3-(5) was
obtained from Molecular Probes, Inc. (Junction City,
OR). Phorbol myristate acetate (PMA) was purchased
from Consolidated Midland, Brewster, N.J. f Met-
Leu-[3H]-Phe (47.6 Ci mmol- ') and L-ax-palmitoyl - 2 -
[palmitoyl - 9,10 - 3H] - phosphatidylcholine, were
purchased from New England Nuclear (Boston,
Mass.). All other chemicals were of analytical reagent
grade.
Buffer
Unless otherwise specified, the buffer used for all
experiments, consisted of (mM): NaCl 140, KCI 5.4,
CaCl2 1.8, MgSO4 0.8, Na2HPO4 0.8, KH2PO4 0.8,
Tris 22.5, glucose 5, pH 7.4. In addition, enzyme
release assays were performed in the presence of
bovine serum albumin 1 mg ml -'.
Results
Effects on lysosomal degranulation
The oligopeptide fMet-Leu-Phe stimulates rat neutro-
phils to release lysosomal enzymes in a dose-depen-
dent manner. Figures la and b show the dose-depen-
dent release of P glucuronidase and lysozyme respec-
tively. Preincubation (10min at 37C) of these cells
with pBPB before stimulation inhibited this degran-
ulation in a dose-dependent manner, such that at
>10 tM, there was a virtually total inhibition of
enzyme release. This inhibition was irreversible as
determined by its persistence after removal of unreac-
























stimulation (data not shown). This inhibition also
showed virtually identical kinetics as the inhibition of
transmembrane potential changes (shown in
Figure 4). pBPB had no effects on the enzyme assays
themselves. These doses ofpBPB also had no effect on
viability as determined by the lack of LDH activity
(above baseline control levels) in the cell supernate.
Effects on superoxide production
The inhibitory effect of pBPB was also observed in
fMet-Leu-Phe stimulation of 0° production. Alth-
ough this peptide is a weak or suboptimal stimulator
of 0° production in rat neutrophils, a clear inhibitory
effect by 5gM pBPB was observed. Thus, 10-6M
fMet-Leu-Phe caused the production of 5.6 ± 0.27
(s.e., n = 3) mmoles by 6 x 106 cellsml-' in 15min,
which reduced to 2.3 ± 0.03 (n = 5) in the presence of
5gM pBPB.
Since rat neutrophils produced relatively small
amounts of 02 upon fMet-Leu-Phe stimulation, we
have confirmed this inhibitory effect using PMA,
which is a more potent stimulant of 0-2 release.
Figure 2 shows a dose-dependent inhibition of 0-2
production by pBPB. In this case, however, I AM was
effective in decreasing 02 production by > 50% at all
doses ofPMA examined, while 5 pM totally abolished
0-2 production. This inhibition was also irreversible
and time-dependent (data not shown).
These data confirm a previous study with a higher
dose of pBPB in human neutrophils (Smolen &
Weissman, 1980). This inhibition was not due to direct
inhibition of the NADPH oxidase itself as shown by
the data in Table 1. These studies revealed that
treatment ofintact cells with 10 JIM pBPB inhibited the
b
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Figure 1 Effect of p-bromophenacyl bromide (pBPB) on (a) P-glucuronidase and (b) lysozyme release following
stimulation with N-formylmethionyl-leucylphenylalanine (fMet-Leu-Phe, fMLP). Varying doses of fMet-Leu-Phe
were added to 4 x 106 neutrophils ml-' treated for 10 min with Me2SO (0.1% final concentration) (0) or pBPB I gM
(-),5 JAM (A) and 10 M (A), washed and resuspended in buffer. Results are expressed as the means of duplicate
determinations of % of total (Triton X-100, 0.1%) releasable activity, with <10% variation.
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Effects on transmembrane potential changes
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Figure 2 Effect ofp-bromophenacyl brn
phorbolmyristate acetate (PMA)-ind
production. Neutrophils (106 ml') were
cytochrome c (80 tiM final concentration
(duplicates) and absence (triplicates) ol
mutase (20 pg ml P'), at 37°C for 60 min.
trations of PMA were added to cell
treated for 10min at 37°C with etha
concentration) (0), or pBPB 1 jIM (0)
Depolarization of the resting cellular transmembrane
potential is an early response of neutrophils to fMet-
Leu-Phe as well as PMA stimulation (Sklar et al.,
1980; Whitin et al., 1980; Duque et al., 1983). Rat
neutrophils showed similar dose-dependent responses
(Figures 3a and b). These changes as probed using the
fluorescent dye diS-C3-(5) (Laris et al., 1976, Whiting
et al., 1980), were also inhibited by pBPB in a dose-
dependent manner, with complete inhibition achieved
-;9 -A- - ~ -6 at doses> 10 ;M (Figures 3a and b). PMA stimulation
revealed greater sensitivity to pBPB. At these doses
pBPB did not affect either partitioning of this fluores-
omide (pBPB) on cent dye or the resting cellular transmembrane poten-
aced superoxide tial as determined by the 'null point' method (Laris et
e incubated with al., 1976) (data not shown). This inhibition was time-
i) in the presence dependent and obeyed pseudo-first order kinetics with
f superoxide dis- rate constant, kapp 0.36 min-' (Figure 4). pBPB
suspension pre- inhibition of isolated and purified pancreatic phos-
mol (0.1% final pholipase A2 also obeys similar kinetics with compara-
and 50M (A). ble kapp (Roberts et al., 1977).
Effects on ligand-receptor binding
PMA-stimulated expression of NADPH oxidase
activity in isolated subcellular particles by 59%. On
the other hand, direct exposure of active subcellular
particle preparations (from PMA stimulated cells) to
pBPB failed to inhibit significantly this NADPH
oxidase activity (11% inhibition). Consequently pBPB
inhibited 02 production by preventing the PMA-in-
duced activation or assembly of the NADPH oxidase
complex without significantly affecting the structural
protein(s) comprising this enzyme complex. To dissect
out more closely the activation process susceptible to
pBPB inhibition, an earlier step of stimulus-response
coupling was examined.
The above data would suggest that pBPB inhibited
these diverse neutrophil responses to two different
stimuli at an early step of cell activation. This step,
however, is not at the level of ligand (f Met-Leu-Phe)-
receptor binding as shown in Table 2. In two separate
experiments, pBPB pretreatment failed to affect sig-
nificantly both the number of binding sites per cell and
the equilibrium dissociation constant, KD. As a matter
of fact, there was a small increase in binding sites per
cell and a slight reduction in KD, which would be more
consistent with increased binding and stimulation
rather than the observed inhibition of functional
responses. Since the functional integrity of the formyl
Table 1 Effect ofp-bromophenacyl bromide (pBPB) on NADPH oxidase activity of subcellular particlesa
Whole cell treatment
PMA (200 mg ml-'
pBPB (10 jiM) + PMA
(200 mg mlP ')
PMA (200 ng ml')
Subcellular
particle °- 2
treatment (nmol mg-' protein)
69.1 ± 2.2
28.3 ±4.5
pBPB (10I'M) 61.4 ± 1.1
aNeutrophils were treated as indicated (under 'whole cell treatment') and subcellular particle isolated as described in
Methods. These particles were then exposed to the treatment as indicated under 'subcellular particle treatment'. They
were then assayed for NADPH-dependent 02 production as described in Methods.
PMA = phorbol myristate acetate.
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Figure 3 Effect ofp-bromophenacyl bromide (pBPB) on transmembrane potential. Neutrophils (2 x 106 ml') were
allowed to equilibrate with 3-3'-dipropylthiodicarbocyanine iodide (2 x 10-6 M) at 37'C. Upon reaching a steady level
of fluorescence intensity, Me2SO (0.1% final concentration) for (a) or ethanol (0.1% final concentration) for (b) (0),
pBPB (IpM) (0), 2 JM (A), 5IZM (A) and lOpM (U) were added. After 8-9min (a) N-formylmethionyl-
leucylphenylalanine (fMLP) or (b) phorbol myristate acetate (PMA) was added at the indicated concentrations. The
results as expressed as the means of triplicate determinations of the maximal change in fluorescence (AF); vertical lines
show s.e.
peptide receptor is dependent on intact free sulphydryl sulphydryls in platelets (Hoffmann et al., 1982). Direct
groups (24,26), this lack of inhibition by pBPB also measurement of the number of titratable sulphydryl
indicated its lack of effect on accessible free sul- groups in whole neutrophils revealed that pBPB at
phydryls. This point is an important one since pBPB at doses of <20 gM had no significant effect on this
high doses (> 50 gM) is known to have non-specific parameter (Table 3). Thus, pBPB inhibition cannot be
effects, such as reducing the number of titratable explained by such non-specific effects.
Effects on phospholipase A2 activity
4.0
The above studies revealed that pBPB inhibited an
early step in the sequence of events leading to neutro-
3.0
'C Figure 4 Kinetics of inhibition of transmembrane
E\ potential changes by p-bromophenacyl bromide (pBPB).Neutrophils (2 x 106 ml') were allowed to equilibrate
> 2.0 * \ with 3-3'-dipropylthiodicarbocyanine iodide (diS-C3-(5))
(2 x 10-6 M). Upon reaching equilibrium, pBPB (5 jAM,
*~\ ~ final concentration) was added. N-formylmethionyl-
o \ leucylphenylalanine (1 x 10-6 M final concentration) was
added after 30 s, 1, 3, 5 and 10 min of incubation with the
\ inhibitor, and the change in fluorescence quantitated.
1.0 Results are expressed as the mean ofduplicate determina-
tions of transmembrane potential changes, with < 10%
variation. The data are presented as a semi-log plot of
remaining activity vs time of incubation with pBPB. The
y-axis labels are natural logarithms of the % of activity
remaining after addition of the indicated concentrations
0 5 10 15 of pBPB (thus 4.6 = 100% activity); linear regression
Time (min) analysis of the data point results in the drawn line.
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24,310 1.7 x 10 8M
28,414 0.74 ± 10-8
p-Bromophenacyl bromide
Binding
sites per cell KD
26,731 1.42 x 10-8M
31,367 0.68 ± 10 8M
'Cells were treated at 37C for 15 min with 10 gM pBPB, washed and assayed for fMet-Leu-[3HJ-Phe binding as
described (see Methods). Determination of the number of binding sites per cell and the dissociation constant (KD) was
made using Scatchard analysis of specific fMet-Leu-[3H]-Phe binding.
phil activation. Although high doses (>50 g1M) of
pBPB have a multitude of effects (Hoffmann et al.,
1982; Kyger & Franson, 1984), these had not been
observed at doses <10p1M (see above). Since this
reagent is an active-site directed inhibitor of phos-
pholipase A2 (Roberts et al., 1977), it seems reasonable
to surmise that pBPB may be inhibiting neutrophil
activation by inhibiting such an enzyme necessary for
the activation process. To test this hypothesis, the
effect of pBPB on neutrophil (both resting and
stimulated) phospholipase A2 was examined.
Assay of whole cell homogenates (from resting and
fMet-Leu-Phe-stimulated cells) revealed <20% in-
hibition of total phospholipase A2 activity by pBPB.
However, when only the subcellular particulate or
membranous fraction (27,000 g pellet) was assayed for
phospholipase A2 pBPB inhibition was more dramatic
(Table 4), and of a similar order of magnitude as its
inhibition of stimulated cellular functional responses.
The data revealed complete inhibition by pBPB of
fMet-Leu-Phe stimulatable activity in these sub-
cellular particles without affecting the resting
enzymatic activity (Table 4). Thus, although pBPB
Table 3 Effect of p-bromophenacyl bromide
(pBPB) on cellular titratable sulphydryl groupsa
failed to inhibit significantly (at least to the extent ofits
inhibition of stimulated cellular functional responses)
whole cell phospholipase A2 activity, it was very
effective in inhibition of the fMet-Leu-Phe stimulata-
ble activity residing in the subcellular pariculate
fraction containing plasma membrane and other
membranous fragments. The ability of fMet-Leu-Phe
to stimulate phospholipase A2 activity in the sub-
cellular particles is in contrast to the lack of such
stimulation in the 100,000 g pellet as reported by
Lanni & Backer (1983). This difference may be due to
the use of H2SO4 to 'extract' the enzyme before assay,
in their study. A subsequent paper from the same
laboratory however, supported our observation of an
inducible phospholipase A2 activity in rabbit neutro-
phil plasma membrane (Bormann et al., 1984). Their
more recent paper also demonstrates the ineffective-
ness ofpBPB in inhibiting phospholipase A2 added to
whole, intact cells (<20%), although this reagent is
highly effective in inhibition of enzyme activity in cell
sonicates or acid extracts (Lanni & Becker, 1985). In
that study however, the effect of fMet-Leu-Phe
stimulation is not examined.
Table 4 Effect of p-bromophenacyl bromide














aS x 106 neutrophils ml-' were incubated with the
indicated concentrations of pBPB for 10 min at
37°C. After washing, the cells were assayed for
titratable sulphydryls as described in Methods.
Data are means ± s.e. of triplicate determinations.









13.4 ± 1.23 7.3 ± 1.70
aData are expressed as mean ± s.e. in units per 107
cells (n = 3). Units of activity are as defined in
Methods.
Cells were treated for 15 min at 37°C in the presence
of 10-5M pBPB, washed and either incubated in
buffer only, or with 106M N-formylmethionyl-
leucylphenylalanine (fMet-Leu-Phe) for 15 min at
37C. Subcellular particles were then obtained and




No. sites per cell
2
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Discussion
The data presented herein suggest a role for a pBPB
inhibitable step(s), in the sequence of events that take
place following receptor-ligand binding and prior to
the secretion phase. These data extend the previously
reported inhibitory effects of pBPB on neutrophil
responses (Smolen & Weissman, 1980) by demonstrat-
ing that an earlier step (membrane potential changes)
is also inhibitable by pBPB. Furthermore, our data
demonstrate that this irreversible and time-dependent
inhibition is not mediated by altering surface receptor
density and ligand-receptor binding kinetics. Nor does
it inhibit by modification of free sulphydryl groups or
the structural proteins comprising the NADPH
oxidase.
The inhibitory effects ofpBPB on membrane poten-
tial changes suggest a requirement for a pBPB-sen-
sitive activity in the production of a state of altered
permeability to ions following stimulation. That a
phospholipase A2-like activity could also be involved
is suggested by recent reports (Yorio et al., 1983)
showing that phospholipid metabolites can contribute
to alteration of membrane permeability in frog skin
epithelium and that the increase in sodium transport
observed is mediated through the release of ara-
chidonic acid and the synthesis of prostaglandins.
Furthermore, a Ca2+-dependent, neutral pH active
phospholipase A2 has been described in rabbit alveolar
macrophages (Franson et al., 1973) and granulocytes
(Franson et al., 1974).
Recent studies by another laboratory have also
reported on a stimulatable phospholipase A2 activity
in rabbit neutrophil plasma membranes (Bormann et
al., 1984). The same laboratory also more recently
noted, that despite the ability of pBPB to inhibit
phospholipase A2 activity in cell sonicates and acid-
extracts, it is only minimally inhibitory (<20%) if
introduced to intact cells (Lanni & Becker, 1985). Our
data are consistent with these findings, and we have
extended them further by reporting inhibition of only
the fMet;Leu-Phe stimulatable enzyme activity.
Additional evidence for the role of a cell bound
phospholipase A2 in the release of arachidonate from
human neutrophil phospholipids has been presented
by Walsh et al. (1980; 1981). The ability of some of
these arachidonate metabolites to initiate and/or
modulate ion fluxes would then have an impact on
transmembrane potential changes.
Although localization and identification of the
target site(s) for pBPB remain uncertain, our data
demonstrate that, with the dose and conditions used,
sulphydryl groups are not affected. This conclusion is
based partially and indirectly on the lack of inhibition
of f Met-Leu-Phe binding, since it is known that intact
sulphydryl groups are essential to maintain the in-
tegrity of the formyl peptide receptor (Schiffmann et
al., 1980; Niedel, 1981). Furthermore, and more
directly we could not demonstrate significant reduc-
tion of cellular titratable sulphydryl groups at concen-
trations of pBPB below 20 tiM. Additionally, if pBPB
were to alter non-specifically free sulphydryl groups,
one would expect inhibition of NADPH oxidase
activity (McPhail et al., 1976). However, this was not
observed and instead pBPB was found to inhibit a
regulatory step other than the structural proteins
involved in the expression of NADPH oxidase
activity. The data would suggest interference with
activation steps required for the expression or assem-
bly ofNADPH oxidase activity and not on the oxidase
itself. In this study pBPB was used at considerably
lower concentrations (< 10 ptM) than was the case in
studies by other investigators who have shown non-
specific inhibitor effects on other enzymes (Hofmann
et al., 1982; Kyger & Franson, 1984). In one of these
studies (Hofmann et al., 1982), 30LM pBPB caused a
63% inhibition of phospholipase C activity after
15 min incubation. Diglyceride lipase was inhibited by
only 56% after 30 min incubation with 500 ZtM pBPB.
These concentratons are from 3- 50 times the maximal
dose used in this study, which could account for the
differences between that study and our data. Another
study purporting to show inhibition of acid proteases
by pBPB (Ackerman et al., 1983) to explain its
neutrophil inhibitory effects, failed to realize that
pBPB does not inhibit acid proteases at pH > 5.0
(Gross & Morell, 1966). In view of these considera-
tions, the effects of pBPB exposure described in this
paper are likely to be due to inhibition of one or more
early regulatory activities, of which a critical mem-
branous fraction of stimulatable cellular phos-
pholipase A2 appears to be a candidate. However,
other sites of inhibition, as yet unidentified cannot be
ruled out at this time especially in view of the
hydrophobic nature of pBPB and its ability to parti-
tion at high local concentrations in membranes. A
possible and as yet unexplored target is the Ca2+-
dependent intracellular signalling system based on the
metabolism of inositol phospholipids (Berridge,
1984).
We conclude: (a) that pBPB at concentrations of
<1O JM inhibit neutrophil functional responses to
several stimuli; (b) the inhibitable step(s) involved in
the stimulus-response process precede the activation
or assembly of the NADPH oxidase required for the
generation ofO2 and (c) the inhibitory effects include
'early' events such as the ligand-induced change in
transmembrane potential. Finally, the inhibition of a
critical membranous fraction of cell bound phos-
pholipase A2 by pBPB would suggest that this enzyme
may be crucial to subsequent cell activation. The
inability to inhibit unstimulated (or 'resting') phos-
pholipase A2 activity would suggest that pBPB may
inhibit the regulatory step(s) necessary for activation
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of this membrane bound phospholipase A2, rather
than alkylating the activatable or activated enzyme
itself. This possibility is also suggested by the ability of
pBPB to inhibit the stimulatable enzyme activity in the
presence of physiological concentrations of Ca2+,
which is known to make the enzyme less susceptible to
alkylation by pBPB (Roberts et al., 1977). There is no
conclusive evidence at this time that the neutrophil
phospholipase A2 contains a histidine at its active site,
although its susceptibility to pBPB inhibition (Lanni
& Lecker, 1985) makes it a likely possibility. Finally,
the available data would not allow any conclusions to
be reached concerning the commonness of the
mechanism by which fMet-Leu-Phe and PMA
stimulate neutrophils.
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